Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
N/A
1(33.3%)
3Total
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05997784Active Not Recruiting

Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing

Role: collaborator

NCT06665919Not ApplicableCompleted

The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models

Role: collaborator

NCT04795557Phase 2Completed

Efficacy of Adaptogens in Patients With Long COVID-19

Role: collaborator

NCT04847518Phase 2Unknown

Assessment of Efficacy of KAN-JANG® in Mild COVID-19

Role: collaborator

All 4 trials loaded